Cerebral aspergillosis: tissue penetration is the key

Area of Science:

• Mycology
• Infectious Diseases
• Neuroscience

Background:

• Cerebral aspergillosis is a severe fungal infection with high mortality, especially in immunocompromised individuals.
• Drug penetration into the central nervous system (CNS) is limited by the blood-brain barrier (BBB), affecting antifungal efficacy.
• Most antifungals have poor CNS penetration due to large molecular size and transporter interactions.

Purpose of the Study:

• To evaluate the efficacy of voriconazole in treating cerebral aspergillosis.
• To assess voriconazole's penetration into the CNS and its concentrations in cerebrospinal fluid (CSF) and brain tissue.
• To explore potential improvements in treatment strategies for neuroaspergillosis.

Main Methods:

• Review of existing data on antifungal drug penetration across the BBB.
• Analysis of voriconazole concentrations in CSF and brain tissue in patients with cerebral aspergillosis.
• Examination of a retrospective study on voriconazole treatment outcomes.
• Consideration of findings from animal models of experimental neuroaspergillosis.

Main Results:

• Voriconazole demonstrated concentrations exceeding inhibitory levels for Aspergillus in CSF and brain tissue.
• A retrospective study showed improved response and survival rates in patients treated with voriconazole.
• Animal models suggest that escalated doses or combination therapies may be beneficial.

Conclusions:

• Voriconazole is a promising agent for cerebral aspergillosis due to its CNS penetration and clinical efficacy.
• Optimizing voriconazole dosing or using combination therapies could further improve outcomes for neuroaspergillosis.
• Cerebral aspergillosis treatment remains challenging, necessitating ongoing research into effective therapeutic strategies.